Raymond James sets USD 140 target for Kymera Therapeutics stock

Published on 10/16/2026 at 03:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kymera reported USD 65.00 million revenue in Q2 2026 versus USD 32.78 million expected. Citi raised its target for Kymera Therapeutics stock to USD 150.

Targets and milestones

Raymond James initiated coverage on October 10, 2026, with a USD 140.00 target.
Second-quarter 2026 revenue reached USD 65.00 million against USD 32.78 million expected.
Citi raised its target from USD 135.00 to USD 150.00 on October 5, 2026.

KYMR, US5015751044, Illustration mit AI erstellt.

Kymera Therapeutics (ISIN US5015751044) received a USD 140.00 price target when Raymond James initiated coverage on October 10, 2026, according to MarketBeat. The brokerage assigned an Outperform rating, putting the clinical-stage biotechnology company back in focus for pipeline-driven valuation.

Analysts raise the valuation bar

The Raymond James target followed Citi's October 5, 2026 decision to lift its target from USD 135.00 to USD 150.00 while keeping a Buy rating, as Markets Insider reported. Citi tied its view to the expected KT-621 readout in atopic dermatitis by the end of 2026.

Kymera's second-quarter 2026 revenue reached USD 65.00 million, compared with USD 32.78 million expected, while adjusted loss per share was USD 0.62 versus a USD 0.71 consensus loss, MarketBeat reported. Revenue therefore exceeded the cited estimate by USD 32.22 million, while the adjusted loss was USD 0.09 per share better than expected.

What does the pipeline mean?

The answer rests on clinical execution rather than current profitability. Kymera describes its platform as targeted protein degradation for oral medicines in chronic inflammatory diseases, with KT-621 among the programs advancing toward later-stage data, according to Kymera Therapeutics.

Three dated steps for KYMR

On August 5, 2026, Kymera reported second-quarter revenue of USD 65.00 million and an adjusted loss of USD 0.62 per share. On October 5, 2026, Citi raised its target from USD 135.00 to USD 150.00. On October 10, 2026, Raymond James initiated coverage with a USD 140.00 target.

Next reporting date

The next listed reporting date is November 3, 2026, for third-quarter 2026 results, according to Eulerpool.

Valuation and risk markers

Kymera had a market capitalization of USD 8.9 billion as of October 15, 2026. Its 52-week range was USD 55.26 to USD 130.05 on the same market-data snapshot, leaving clinical results as the central test for the targets described above.